Leukemia be introduced into the therapy of childhood AML with great caution and only if they prove to have a strong beneficial effect in adult AML.
Figure 2
MDR1 gene expression and overall survival. The median was used as cutoff for high and low expression. The difference between the two groups was not statistically significant. N, number of patients; OS, overall survival; SE, standard error.
in 20 samples from children with AML. No correlation of P-gp with resistance to daunorubicin, vincristine or etoposide was found.
We analyzed nine patients at initial stage as well as in first relapse. A trend for higher levels of MDR1 gene expression at the time of relapse was found but this trend was not statistically significant (Wilcoxon test P = 0.13).
It is difficult to say why the prognostic relevance of P-gp in childhood AML could be different from adult patients. One possible explanation it that most pediatric therapy regimens are more intensive than those which are applied in adult patients. Thus, drug resistance mediated by P-gp could be overcome by the higher dosage and the higher number of co-administered drugs.
The major limitation of this study is that our patients were treated according to four different multi-center studies. 3 However, the expression of MDR1 was evenly distributed among the four studies and to avoid a bias due to the different outcome in the four studies all calculations were repeated, using the number of the study as a stratification variable.
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Internal tandem duplications of FLT3 gene, that represents a strong prognostic factor for overall survival (OS) in AML patients younger than 60 years, seems a rare event in t(8;21) and inv(16)/t(16;16). [1] [2] [3] By contrast, c-kit point mutations are more frequently described in core binding factor (CBF) leukemia; in this setting we previously reported the presence of both D816Y and D816V point mutations in six of 15 patients (40%) [4] [5] [6] and Gari et al 7 found an incidence of the c-kit proto-oncogene deletion plus insertion mutations of 33% among 21 patients with inv(16) and of 5% in patients with t(8;21). However little is known about their prognostic significance.
Recently a retrospective multicenter study on 154 adults and children with t(8;21) AML demonstrated that the WBC index (expressed as WBC × [% marrow blasts/100]) was the only prognostic factor for disease-free survival (DFS), complete remission (CR) duration and OS. 8 
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Figure 1
Analysis of WBC-count (a) and WBC index (b) in the 12 t(8;21) AML patients according to the presence (c-kit+) or the absence (c-kit−) of c-kit mutation.
To investigate the impact of c-kit gene mutations in CBF-AML, we attempted correlating the presence of the mutation with the WBC count and the level of WBC index, in 18 consecutive patients. The 18 patients, 12 male and six female, aged up to 60 years, had a median age of 41 years (range 16-60); cytogenetic showed a t(8;21) in 12 cases and an inv(16) in the remaining six cases. On the basis of mutational screening, 6 eight patients, six t(8;21) and two inv(16), were categorized in the 'c-kit point mutation group' (c-kit+) and 10, in which the mutation was not detected, in the c-kit negative group (c-kit−). Considering the whole group of patients we found a median WBC count of 19. + cells/kg. 9 Six stem cell transplants (SCT) were performed instead of the third consolidation course: three autologous-SCT (one in the c-kit+ group) and three allogeneic-SCT (one in the c-kit+ group). Considering the whole group of 18 CBF-AML patients, at a median follow-up of 18.5 months (range 1-84), we record for c-kit+ and ckit−, respectively: CR incidence of 87.5% vs 90%, relapse incidence 85.7% vs 44% (P = NS), OS 25% (2/8 patients) vs 60% (6/10 patients, P = NS) and the DFS 14.2% (1/7 patients) vs 66% (6/9, P = 0.07). It is noteworthy that among the eight patients presenting with activating mutation of c-kit gene, only one is still alive and in hematological and cytogenetical CR after ASCT. In conclusion, our study demonstrates the correlation between c-kit mutational status with high WBC count and WBC index in the t(8;21) CBF-AML patients. Furthermore our data showed a weak statistical correlation between the presence of c-kit mutation and the DFS, even if the trial has not been extended to draw a final conclusion. It is extremely important to spread the study to a larger number of patients in order to obtain the most accurate results. 
